Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis Clinical Trial
Official title:
Long-term Follow-up at 10 Years of Patients Enrolled in the Fingolimod Phase II Program in Relapsing Multiple Sclerosis
This study aims to collect follow-up data on approximately 90% of patients who were randomized and received one dose of study drug in FTY720D2201. No study drug is given or required. Patients will be required to be assessed at one or two visits, preferably at the original study site, but the option to be interviewed via phone or seen at home is provided. Information will also be gathered on deceased patients. Assessments will be performed only once within an 8 week period and include medical history, Multiple Sclerosis (MS) and Multiple Sclerosis Disease Modifying Therapy (MS DMT) history, Expanded Disability Status Scale (EDSS), Magnetic Resonance Imaging (MRI), Multiple Sclerosis Functional Composite (MSFC).
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label